Bridgebio therapeutics focuses on the manufacturing of basic pharmaceutical substances and biological products, as well as the research and development of medical and pharmaceutical products. It has set idiopathic pulmonary fibrosis and cancer, which is the target of targeted therapies, as its key areas of focus, and is engaged in the research and development of innovative new drug candidates that meet the needs of patients and the market. The company has independently discovered BBT-207, a next-generation non-small cell lung cancer treatment candidate, and is conducting clinical trials. It is also progressing with clinical trials for BBT-877, a treatment candidate for idiopathic pulmonary fibrosis.

BBT-877 : Orally administered autotaxin enzyme inhibitor which is under development as a treatment for various fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) BBT-207 : A mutant selective and broad-spectrum fourth-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) BBT-401 : Once-daily orally administered pellino-1 protein inhibitor, currently in Phase II clinical trials and is under development as a treatment for ulcerative colitis.

Public

Biotech